CORT Form 4: CDO exercises 20,000 options, sells 20,000 shares

Corcept Therapeutics (CORT) Chief Development Officer William Guyer reported transactions on 11/05/2025.

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) Chief Development Officer William Guyer reported transactions on 11/05/2025. He exercised 20,000 stock options at $21.65 and sold a total of 20,000 shares in multiple trades, including 6,536 shares at a weighted average of $74.7489, 13,164 shares at $75.6365, and 300 shares at $76.28. Following these trades, he directly owned 5,287 shares and held 290,000 derivative securities (options) afterward. The transactions were made under a Rule 10b5-1 plan adopted on November 27, 2024.

Insider Trade Summary

Exercise and Sale: 20,000 shares ($1.07M approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Guyer William

Role Chief Development Officer

Sold 20,000 shs ($1.51M)

Approx. gross sale proceeds $1.51M

Approx. exercise cost $433K

Approx. pre-tax spread $1.07M

Type	Security	Shares	Price	Value
Exercise	Stock option (right to buy)	20,000	$0.00	$0.00
Exercise	Common Stock	20,000	$21.65	$433K
Sale	Common Stock	6,536	$74.7489	$489K
Sale	Common Stock	13,164	$75.6365	$996K
Sale	Common Stock	300	$76.28	$23K

Holdings After Transaction: Stock option (right to buy) — 290,000 contracts (Direct); Common Stock — 5,287 shares (Direct)

Footnotes (4)

1. F1. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
2. F2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.17 to $75.165 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
3. F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $75.185 to $76.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
4. F4. Fully exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CORT's CDO William Guyer report on Form 4?

He exercised 20,000 options at $21.65 and sold 20,000 shares on 11/05/2025 across multiple trades.

What were the sale prices disclosed for CORT shares?

Weighted averages were $74.7489, $75.6365, and a trade at $76.28. The filing provides price ranges for the weighted-average lots.

How many CORT shares does William Guyer own after the transactions?

He directly owned 5,287 shares after the reported transactions.

How many options does William Guyer hold after the transactions?

He beneficially owned 290,000 derivative securities (stock options) afterward.

Were the CORT share sales under a 10b5-1 plan?

Yes. The transactions were made under a Rule 10b5-1 plan adopted on November 27, 2024.

What is the earliest transaction date on the Form 4?

The earliest transaction date is 11/05/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 05:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2025		M		20,000	A	$21.65	25,287	D
Common Stock	11/05/2025		S(1)		6,536	D	$74.7489(2)	18,751	D
Common Stock	11/05/2025		S(1)		13,164	D	$75.6365(3)	5,587	D
Common Stock	11/05/2025		S(1)		300	D	$76.28	5,287	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$21.65	11/05/2025		M			20,000	(4)	09/01/2031	Common Stock	20,000	$0	290,000	D

Explanation of Responses:

1. The transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.17 to $75.165 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $75.185 to $76.17 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.